Erasca Inc (ERAS) Stock Price, Quote & News - Mboum

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

JrNannies Aug. 18 at 4:29 PM

0 · Reply

JarvisFlow Aug. 18 at 12:00 PM

Morgan Stanley updates rating for Erasca ( $ERAS ) to Equal-Weight, target set at 4 → 2.

0 · Reply

outlawinvestor1 Aug. 17 at 10:53 PM

$ERAS always reassuring when the mgmt team and bod are buying their shares.

1 · Reply

vu_jade Aug. 15 at 4:58 PM

$ERAS bounce

0 · Reply

outlawinvestor1 Aug. 14 at 2:13 PM

$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX

1 · Reply

JrNannies Aug. 13 at 4:09 PM

0 · Reply

JrNannies Aug. 13 at 2:51 PM

0 · Reply

JrNannies Aug. 13 at 1:40 PM

0 · Reply

JrNannies Aug. 12 at 8:14 PM

$ERAS october 2025 potential drug news get in before price goes to $2

1 · Reply

JrNannies Aug. 11 at 7:55 PM

$ERAS when is earnings report

0 · Reply

Latest News on ERAS

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Aug 12, 2025, 4:01 PM EDT - 6 days ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Jun 2, 2025, 8:00 AM EDT - 2 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 2 months ago

Erasca to Present at Upcoming Investor Conferences in June

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 4:05 PM EDT - 3 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 13, 2025, 8:00 AM EDT - 3 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Erasca to Present at the Bank of America Securities Health Care Conference

May 7, 2025, 8:00 AM EDT - 3 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 29, 2025, 4:05 PM EDT - 3 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 4 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 5 months ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Mar 20, 2025, 4:01 PM EDT - 5 months ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 7 months ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 7 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 12, 2024, 4:01 PM EST - 9 months ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 10 months ago

Erasca to Present at Upcoming Investor Conferences

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca to Present at the Bank of America Health Care Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 29, 2024, 11:11 AM EDT - 1 year ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 8:30 PM EDT - 1 year ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Dec 11, 2023, 8:00 AM EST - 1 year ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 28, 2023, 8:00 AM EST - 1 year ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 9, 2023, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Erasca to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences in November

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 22, 2023, 4:01 PM EDT - 2 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 16, 2023, 8:00 AM EDT - 2 years ago

Erasca Further Strengthens Business Leadership with Two Key Promotions

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 15, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2023 Financial Results and Business Updates

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 2, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

May 1, 2023, 8:00 AM EDT - 2 years ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting

Mar 14, 2023, 4:31 PM EDT - 2 years ago

Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting

Erasca: Potential Strong Upside Ahead

Feb 8, 2023, 11:21 AM EST - 2 years ago

Erasca: Potential Strong Upside Ahead

MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge

Feb 6, 2023, 8:01 AM EST - 2 years ago

MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge

BA CACC CAT CELH CRM CVX DIS

JrNannies Aug. 18 at 4:29 PM

0 · Reply

JarvisFlow Aug. 18 at 12:00 PM

Morgan Stanley updates rating for Erasca ( $ERAS ) to Equal-Weight, target set at 4 → 2.

0 · Reply

outlawinvestor1 Aug. 17 at 10:53 PM

$ERAS always reassuring when the mgmt team and bod are buying their shares.

1 · Reply

vu_jade Aug. 15 at 4:58 PM

$ERAS bounce

0 · Reply

outlawinvestor1 Aug. 14 at 2:13 PM

$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX

1 · Reply

JrNannies Aug. 13 at 4:09 PM

0 · Reply

JrNannies Aug. 13 at 2:51 PM

0 · Reply

JrNannies Aug. 13 at 1:40 PM

0 · Reply

JrNannies Aug. 12 at 8:14 PM

$ERAS october 2025 potential drug news get in before price goes to $2

1 · Reply

JrNannies Aug. 11 at 7:55 PM

$ERAS when is earnings report

0 · Reply

airbell Aug. 1 at 1:42 PM

$ERAS added

1 · Reply

Chad_Thunderstock Aug. 1 at 1:02 PM

$ERAS will probably dip to 1.20s and 1.30s and then poo up to 2 dollars

0 · Reply

Chad_Thunderstock Jul. 28 at 3:45 PM

$ERAS this stock is very predictable. Lots of buying and manipulation to shake out investors. I'm seeing it everyday on here.

0 · Reply

JrNannies Jul. 24 at 5:25 PM

0 · Reply

Chad_Thunderstock Jul. 23 at 8:42 PM

$ERAS not selling until 2.20.

0 · Reply

vu_jade Jul. 23 at 5:09 PM

$ERAS soon

0 · Reply

Chad_Thunderstock Jul. 23 at 4:01 PM

$ERAS still here.

1 · Reply

JrNannies Jul. 23 at 2:30 PM

$ERAS what news or whats going on

1 · Reply

makedatbread88 Jul. 22 at 9:29 PM

$ALLR $CDIO $ERAS All up since my alert ***Follow me for more winning calls***

0 · Reply

Chartwatcher1 Jul. 22 at 7:38 PM

$ERAS adding

0 · Reply

JrNannies Jul. 22 at 2:48 PM

$ERAS any news

0 · Reply

boohoooomillenials Jul. 9 at 4:52 PM

$ERAS about to make a move $WOLF $SBET

1 · Reply